Arrowhead Pharmaceuticals vs Arbutus Biopharma: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Arrowhead Pharmaceuticals Inc (ARWR)

Q3 202622 Jun – 30 Aug 2026

▲3

Arrowhead's RNAi pipeline advances with EU launch and Phase 3 wins

EU approval of REDEMPLO opens first market Arrowhead won European Commission approval for REDEMPLO, the first siRNA treatment for familial chylomicronemia syndrome. This opens a new revenue stream and validates its RNAi platform, lifting investor expectations for future drug approvals and sales.
First regulatory approval in a major market is a key catalyst for ARWR's commercial future.
Plozasiran Phase 3 success pressures rival Ionis Plozasiran met all endpoints in two Phase 3 trials for severe hypertriglyceridemia, cutting triglycerides by ~80% and pancreatitis events by 78%. This positions ARWR ahead of Ionis's competing drug, boosting confidence in a large market opportunity.
Late-stage win with best-in-class potential directly boosts ARWR's competitive position and future sales outlook.
Zodasiran enrollment complete for HoFH Arrowhead finished enrolling 70 patients in the Phase 3 YOSEMITE trial of zodasiran for homozygous familial hypercholesterolemia, ahead of schedule. This keeps another pipeline drug on track for a 2027 readout, adding long-term value.
Pipeline progress reduces reliance on a single drug and supports future growth.
Q3 loss widens but revenue beats and cash remains strong Arrowhead reported a $194 million quarterly loss and spent $215 million on a priority review voucher, but revenue jumped 171% to $75 million and cash stands at $1.6 billion. The voucher could speed FDA review of plozasiran, while the loss highlights heavy spending.
Financials show both growing commercial traction and ongoing cash burn, a key tension for investors.

July 202622 Jun – 30 Aug 2026

▲3

Arrowhead's RNAi pipeline advances with EU launch and Phase 3 wins

EU approval of REDEMPLO opens first market Arrowhead won European Commission approval for REDEMPLO, the first siRNA treatment for familial chylomicronemia syndrome. This opens a new revenue stream and validates its RNAi platform, lifting investor expectations for future drug approvals and sales.
First regulatory approval in a major market is a key catalyst for ARWR's commercial future.
Plozasiran Phase 3 success pressures rival Ionis Plozasiran met all endpoints in two Phase 3 trials for severe hypertriglyceridemia, cutting triglycerides by ~80% and pancreatitis events by 78%. This positions ARWR ahead of Ionis's competing drug, boosting confidence in a large market opportunity.
Late-stage win with best-in-class potential directly boosts ARWR's competitive position and future sales outlook.
Zodasiran enrollment complete for HoFH Arrowhead finished enrolling 70 patients in the Phase 3 YOSEMITE trial of zodasiran for homozygous familial hypercholesterolemia, ahead of schedule. This keeps another pipeline drug on track for a 2027 readout, adding long-term value.
Pipeline progress reduces reliance on a single drug and supports future growth.
Q3 loss widens but revenue beats and cash remains strong Arrowhead reported a $194 million quarterly loss and spent $215 million on a priority review voucher, but revenue jumped 171% to $75 million and cash stands at $1.6 billion. The voucher could speed FDA review of plozasiran, while the loss highlights heavy spending.
Financials show both growing commercial traction and ongoing cash burn, a key tension for investors.

Latest22 Jun – 30 Aug 2026

▲3

Arrowhead's RNAi pipeline advances with EU launch and Phase 3 wins

EU approval of REDEMPLO opens first market Arrowhead won European Commission approval for REDEMPLO, the first siRNA treatment for familial chylomicronemia syndrome. This opens a new revenue stream and validates its RNAi platform, lifting investor expectations for future drug approvals and sales.
First regulatory approval in a major market is a key catalyst for ARWR's commercial future.
Plozasiran Phase 3 success pressures rival Ionis Plozasiran met all endpoints in two Phase 3 trials for severe hypertriglyceridemia, cutting triglycerides by ~80% and pancreatitis events by 78%. This positions ARWR ahead of Ionis's competing drug, boosting confidence in a large market opportunity.
Late-stage win with best-in-class potential directly boosts ARWR's competitive position and future sales outlook.
Zodasiran enrollment complete for HoFH Arrowhead finished enrolling 70 patients in the Phase 3 YOSEMITE trial of zodasiran for homozygous familial hypercholesterolemia, ahead of schedule. This keeps another pipeline drug on track for a 2027 readout, adding long-term value.
Pipeline progress reduces reliance on a single drug and supports future growth.
Q3 loss widens but revenue beats and cash remains strong Arrowhead reported a $194 million quarterly loss and spent $215 million on a priority review voucher, but revenue jumped 171% to $75 million and cash stands at $1.6 billion. The voucher could speed FDA review of plozasiran, while the loss highlights heavy spending.
Financials show both growing commercial traction and ongoing cash burn, a key tension for investors.

Arbutus Biopharma Corp (ABUS)

Q3 202616 Jul – 30 Sep 2026

▲4

Arbutus turns patent wins into cash and a big share buyback

New patent suits against Pfizer and BioNTech Arbutus and partner Genevant sued Pfizer and BioNTech in Canada and Europe over the lipid nanoparticle technology used in their COVID vaccine, seeking injunctions and damages. If Arbutus wins or settles, it could collect royalties or a lump sum, which would lift the stock.
This is the period's main new legal catalyst that could bring Arbutus more money.
Moderna pays $178M; up to $230M to shareholders Arbutus received about $178 million from its $950 million Moderna patent settlement and said it will return up to roughly $230 million to shareholders through buybacks. Real cash in hand and a plan to hand it back supports the share price.
It shows the patent money is real and being used to reward shareholders.
$230M tender offer at $5.00-$5.75 a share Arbutus launched a modified Dutch auction to buy back up to $230 million of stock at $5.00 to $5.75 per share, funded from cash on hand. A buyback at a set price can put a floor under the stock and signals management thinks it is cheap.
The buyback is the concrete action that moves the share price this period.
Buyback final: 46M shares at $5 each Arbutus will cancel about 46 million shares at $5 each, roughly 23% of the company, leaving nearly 153.3 million shares outstanding. Fewer shares means each remaining share owns more of the company, which can raise the value per share.
It is the completed result of the buyback and changes Arbutus's share count.

August 202616 Jul – 30 Sep 2026

▲4

Arbutus turns patent wins into cash and a big share buyback

New patent suits against Pfizer and BioNTech Arbutus and partner Genevant sued Pfizer and BioNTech in Canada and Europe over the lipid nanoparticle technology used in their COVID vaccine, seeking injunctions and damages. If Arbutus wins or settles, it could collect royalties or a lump sum, which would lift the stock.
This is the period's main new legal catalyst that could bring Arbutus more money.
Moderna pays $178M; up to $230M to shareholders Arbutus received about $178 million from its $950 million Moderna patent settlement and said it will return up to roughly $230 million to shareholders through buybacks. Real cash in hand and a plan to hand it back supports the share price.
It shows the patent money is real and being used to reward shareholders.
$230M tender offer at $5.00-$5.75 a share Arbutus launched a modified Dutch auction to buy back up to $230 million of stock at $5.00 to $5.75 per share, funded from cash on hand. A buyback at a set price can put a floor under the stock and signals management thinks it is cheap.
The buyback is the concrete action that moves the share price this period.
Buyback final: 46M shares at $5 each Arbutus will cancel about 46 million shares at $5 each, roughly 23% of the company, leaving nearly 153.3 million shares outstanding. Fewer shares means each remaining share owns more of the company, which can raise the value per share.
It is the completed result of the buyback and changes Arbutus's share count.

Latest16 Jul – 30 Sep 2026

▲4

Arbutus turns patent wins into cash and a big share buyback

New patent suits against Pfizer and BioNTech Arbutus and partner Genevant sued Pfizer and BioNTech in Canada and Europe over the lipid nanoparticle technology used in their COVID vaccine, seeking injunctions and damages. If Arbutus wins or settles, it could collect royalties or a lump sum, which would lift the stock.
This is the period's main new legal catalyst that could bring Arbutus more money.
Moderna pays $178M; up to $230M to shareholders Arbutus received about $178 million from its $950 million Moderna patent settlement and said it will return up to roughly $230 million to shareholders through buybacks. Real cash in hand and a plan to hand it back supports the share price.
It shows the patent money is real and being used to reward shareholders.
$230M tender offer at $5.00-$5.75 a share Arbutus launched a modified Dutch auction to buy back up to $230 million of stock at $5.00 to $5.75 per share, funded from cash on hand. A buyback at a set price can put a floor under the stock and signals management thinks it is cheap.
The buyback is the concrete action that moves the share price this period.
Buyback final: 46M shares at $5 each Arbutus will cancel about 46 million shares at $5 each, roughly 23% of the company, leaving nearly 153.3 million shares outstanding. Fewer shares means each remaining share owns more of the company, which can raise the value per share.
It is the completed result of the buyback and changes Arbutus's share count.